

SPARC/Sec/SE/2021-22/39

August 25, 2021

National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051.

BSE Limited,

Market Operations Dept. P. J. Towers, Dalal Street, Mumbai - 400 001.

Ref: Scrip Code: NSE: SPARC; BSE: 532872

Dear Sir/ Madam,

Sub: Intimation of Outcome of the meeting of the Securities Allotment Committee held today i.e. on August 25, 2021 in terms of Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We refer to our letter dated July 08, 2021 bearing reference no. SPARC/Sec/SE/2021-22/32, whereby an intimation was made w.r.t. allotment of 6,24,74,082 warrants, each convertible into or exchangeable for one fully paid up equity share of Re. 1 each of the Company, at an issue price of Rs. 178/- on preferential basis to 31 allottees (warrant holders), as per the list forming part of the said letter.

Pursuant to the provisions of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, the warrant holders had paid 25% (Rs. 44.50/- per warrant) of the issue price of the warrant as the warrant subscription price. The balance 75% (Rs.133.50/- per warrant) of the issue price of warrants was to be paid at the time of exercise of option to apply for fully paid –up Equity shares of Re. 1/- each of the Company, against each such warrants held by the warrant holder.

In view of above and upon receipt from one of the warrant holder, a written notice and balance 75% (at the rate of Rs. 133.50/- per warrant) for the warrants so held, the Securities Allotment Committee of the Company at its meeting held today i.e. August 25, 2021 has allotted 14,04,494 equity shares of Re. 1/- each, upon conversion / exchange of equal number of warrants, as per the details given below:

Name of the warrant holder	Number of warrants held	Balance Amount (In Rs.) Received (@133.50 per warrant)	Number of equity shares allotted, upon conversion / exchange of warrants
Abakkus Growth Fund - 1	14,04,494	18,74,99,949	14,04,494

The new equity shares so allotted, shall rank *pari passu* with the existing equity shares of the Company.

Sun Pharma Advanced Research Company Ltd.

17/B, Mahal Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India. Tel.: (91-22) 6645 5645 | Fax.: (91-22) 6645 5685 | CIN: L73100GJ2006PLC047837 | Website: www.sparc.life



Post the above allotment, the paid up capital of the Company has increased from Rs. 26,20,47,506 (26,20,47,506 equity shares of face value of Re. 1/- each fully paid up) to Rs. 26,34,52,000/- (26,34,52,000 equity shares of face value of Re. 1/- each fully paid up).

The meeting of the Committee commenced at 11:00 A.M. and concluded at 11:30 A.M.

Thanking you,

Yours faithfully,

For Sun Pharma Advanced Research Company Limited

Dinesh Lahoti Company Secretary and Compliance Officer ICSI Membership No. A22471